• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

膀胱过度活动症:基层医疗保健提供者概述

The overactive bladder: an overview for primary care health providers.

作者信息

Wein A J, Rovner E S

机构信息

Division of Urology, University of Pennsylvania School of Medicine, Philadelphia 19104, USA.

出版信息

Int J Fertil Womens Med. 1999 Mar-Apr;44(2):56-66.

PMID:10338262
Abstract

The overactive bladder, with symptoms of frequency, urgency and urge incontinence, substantially affects the life styles of millions of people throughout the world. The symptoms are associated with significant social, psychological, occupational, domestic, physical, and sexual problems. Despite the considerable impact of the condition on quality of life, sufferers are often reluctant to discuss their problem with family members or health care professionals. This state of affairs is unfortunate, for much can be done to alleviate the symptoms of this distressing condition. It is therefore of utmost importance that medical education about symptoms of the overactive bladder and other related problems be improved, to help health care professionals identify and treat patients who will benefit from therapy. This article reviews current thinking regarding definition, epidemiology, quality of life effects, evaluation and management. Emphasis is placed on knowledge particularly useful in primary care, especially, noninvasive modalities of therapy.

摘要

膀胱过度活动症,伴有尿频、尿急和急迫性尿失禁症状,严重影响着全球数百万人的生活方式。这些症状与严重的社会、心理、职业、家庭、身体和性方面的问题相关。尽管该病症对生活质量有相当大的影响,但患者往往不愿与家人或医疗保健专业人员讨论他们的问题。这种情况很不幸,因为可以采取很多措施来缓解这种令人痛苦的病症的症状。因此,改善关于膀胱过度活动症症状及其他相关问题的医学教育至关重要,以帮助医疗保健专业人员识别并治疗能从治疗中受益的患者。本文综述了关于定义、流行病学、生活质量影响、评估和管理的当前观点。重点放在对初级保健特别有用的知识上,尤其是非侵入性治疗方式。

相似文献

1
The overactive bladder: an overview for primary care health providers.膀胱过度活动症:基层医疗保健提供者概述
Int J Fertil Womens Med. 1999 Mar-Apr;44(2):56-66.
2
Evaluation and treatment of the overactive bladder.膀胱过度活动症的评估与治疗
Rev Hosp Clin Fac Med Sao Paulo. 2002 Jan-Feb;57(1):39-48. doi: 10.1590/s0041-87812002000100007.
3
Overactive bladder significantly affects quality of life.膀胱过度活动症严重影响生活质量。
Am J Manag Care. 2000 Jul;6(11 Suppl):S580-90.
4
Defining overactive bladder: epidemiology and burden of disease.膀胱过度活动症的定义:流行病学与疾病负担
Urology. 2004 Dec;64(6 Suppl 1):2-6. doi: 10.1016/j.urology.2004.10.047.
5
Prevalence and burden of overactive bladder in the United States.美国膀胱过度活动症的患病率及负担
World J Urol. 2003 May;20(6):327-36. doi: 10.1007/s00345-002-0301-4. Epub 2002 Nov 15.
6
Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.索利那新用于治疗伴有尿失禁的膀胱过度活动症:症状困扰及与健康相关的生活质量结果
Ann Pharmacother. 2007 Mar;41(3):391-8. doi: 10.1345/aph.1H581. Epub 2007 Mar 6.
7
Reversing the tide: emerging options for treating overactive bladder symptoms in women.
Tex Med. 1999 Nov;95(11):78-81.
8
Overactive bladder: treatment options in primary care medicine.
J Am Osteopath Assoc. 2007 Sep;107(9):379-85.
9
[Overactive bladder syndrome. How to manage it].[膀胱过度活动症。如何应对]
Hokkaido Igaku Zasshi. 2009 Mar;84(2):73-6.
10
Overactive bladder--a practical approach to evaluation and management.膀胱过度活动症——评估与管理的实用方法
J Med Liban. 2004 Oct-Dec;52(4):220-6.

引用本文的文献

1
Do we need more patient-friendly treatment options for overactive bladder (OAB)?我们是否需要更多针对膀胱过度活动症(OAB)的患者友好型治疗选择?
Neurourol Urodyn. 2021 Aug;40(6):1433-1440. doi: 10.1002/nau.24731. Epub 2021 Jun 21.
2
Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies.米拉贝隆治疗膀胱过度活动症:三项随机、双盲、安慰剂对照、III 期研究的预先设定的汇总疗效分析和汇总安全性分析。
Int J Clin Pract. 2013 Jul;67(7):619-32. doi: 10.1111/ijcp.12194. Epub 2013 May 21.
3
AE9C90CB: a novel, bladder-selective muscarinic receptor antagonist for the treatment of overactive bladder.
AE9C90CB:一种新型、膀胱选择性毒蕈碱受体拮抗剂,用于治疗膀胱过度活动症。
Br J Pharmacol. 2010 Jul;160(5):1119-27. doi: 10.1111/j.1476-5381.2010.00752.x.
4
The overlap of interstitial cystitis/painful bladder syndrome and overactive bladder.间质性膀胱炎/膀胱疼痛综合征与膀胱过度活动症的重叠
JSLS. 2010 Jan-Mar;14(1):83-90. doi: 10.4293/108680810X12674612014743. Epub 2010 Apr 21.
5
Maximizing the treatment of overactive bladder in the elderly.优化老年膀胱过度活动症的治疗
Rev Urol. 2008 Winter;10(1):6-13.
6
Absolute bioavailability of imidafenacin after oral administration to healthy subjects.口服给予健康受试者后咪达非那新的绝对生物利用度。
Br J Clin Pharmacol. 2008 Feb;65(2):197-202. doi: 10.1111/j.1365-2125.2007.02999.x.
7
Related factors of urge, stress, mixed urinary incontinence and overactive bladder in reproductive age women in Tabriz, Iran: a cross-sectional study.伊朗大不里士育龄妇女急迫性、压力性、混合性尿失禁及膀胱过度活动症的相关因素:一项横断面研究
Int Urogynecol J Pelvic Floor Dysfunct. 2008 Mar;19(3):367-73. doi: 10.1007/s00192-007-0437-2. Epub 2007 Aug 18.
8
Urodynamic effects of oxybutynin and tolterodine in conscious and anesthetized rats under different cystometrographic conditions.奥昔布宁和托特罗定在不同膀胱测压条件下对清醒和麻醉大鼠的尿动力学影响。
BMC Pharmacol. 2005 Oct 11;5:14. doi: 10.1186/1471-2210-5-14.
9
Multinational study of reliability and validity of the King's Health Questionnaire in patients with overactive bladder.
Qual Life Res. 2003 Jun;12(4):427-42. doi: 10.1023/a:1023422208910.
10
Long-term safety of extended-release oxybutynin chloride in a community-dwelling population of participants with overactive bladder: a one-year study.在社区居住的膀胱过度活动症参与者群体中,氯苯氧胺缓释剂的长期安全性:一项为期一年的研究。
Int Urol Nephrol. 2002;34(1):43-9. doi: 10.1023/a:1021372426421.